Title:
COMBINED MEDICINE COMPRISING GEMCITABINE-ENCAPSULATED LIPOSOME COMPOSITION AND IMMUNE CHECKPOINT BLOCKADE
Document Type and Number:
WIPO Patent Application WO/2019/244978
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a medicine prepared by combining a liposome composition with an immune checkpoint blockade, wherein gemcitabine is encapsulated in a dissolved state in liposomes in the liposome composition. According to the present invention, a medicine which is a combination of (A) a liposome composition with (B) an immune checkpoint blockade is provided, wherein the liposome composition comprises liposomes each having an inner aqueous phase and an aqueous solution constituting an outer aqueous phase and having the liposomes dispersed therein, gemcitabine is encapsulated in a dissolved state in the liposomes, and the liposome composition and the immune checkpoint blockade are administered simultaneously or sequentially.
Inventors:
KOMORI TAKASHI (JP)
IOROI TADAAKI (JP)
MATSUMOTO TAKESHI (JP)
IZUMI YASUYUKI (JP)
IOROI TADAAKI (JP)
MATSUMOTO TAKESHI (JP)
IZUMI YASUYUKI (JP)
Application Number:
PCT/JP2019/024499
Publication Date:
December 26, 2019
Filing Date:
June 20, 2019
Export Citation:
Assignee:
FUJIFILM CORP (JP)
International Classes:
A61K31/7068; A61K9/127; A61K39/395; A61K45/00; A61K47/28; A61P35/00; A61P37/04; A61P43/00
Domestic Patent References:
| WO2017078008A1 | 2017-05-11 | |||
| WO2006121168A1 | 2006-11-16 | |||
| WO2015166985A1 | 2015-11-05 | |||
| WO2015166986A1 | 2015-11-05 |
Foreign References:
| JP2006340714A | 2006-12-21 |
Other References:
WANG C. ET AL.: "In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy", SCIENCE TRANSLATIONAL MEDICINE, vol. 10, February 2018 (2018-02-01), pages eaan3682, XP055648279
ONO ONCOLOGY OPDIVO Q&A: "Can Opdivo be used in combination with chemotherapeutic agents?", 2 May 2018, ONO PHARMACEUTICAL CO., LTD.
IMMUNOLOGY, vol. 138, no. 2, 2013, pages 105 - 115
J CLIN INVEST, vol. 122, no. 3, 2012, pages 787 - 95
JOURNAL OF JAPAN SOCIETY OF IMMUNOLOGY & ALLERGOLOGY IN OTOLARYNGOLOGY (JJIAO, vol. 30, no. 4, 2013, pages 271 - 278
See also references of EP 3811949A4
ONO ONCOLOGY OPDIVO Q&A: "Can Opdivo be used in combination with chemotherapeutic agents?", 2 May 2018, ONO PHARMACEUTICAL CO., LTD.
IMMUNOLOGY, vol. 138, no. 2, 2013, pages 105 - 115
J CLIN INVEST, vol. 122, no. 3, 2012, pages 787 - 95
JOURNAL OF JAPAN SOCIETY OF IMMUNOLOGY & ALLERGOLOGY IN OTOLARYNGOLOGY (JJIAO, vol. 30, no. 4, 2013, pages 271 - 278
See also references of EP 3811949A4
Attorney, Agent or Firm:
SIKs & Co. (JP)
Download PDF: